Previous 10 | Next 10 |
2023-11-09 17:45:48 ET More on Context Therapeutics Seeking Alpha’s Quant Rating on Context Therapeutics Historical earnings data for Context Therapeutics Financial information for Context Therapeutics For further details see: Context Therapeutics ...
CTIM-76 IND filing on track for late Q1 2024 Cash and cash equivalents of $21.7 million as of September 30, 2023 Company expects its cash and cash equivalents will continue to fund operations into late 2024 PHILADELPHIA, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Context Therapeuti...
Evotec SE (EVO) is expected to report $-0.03 for Q3 2023 Amplifon (AMFPF) is expected to report for Q3 2023 Compass Therapeutics Inc. (CMPX) is expected to report $-0.11 for Q3 2023 Astronics Corp. - Class B (ATROB) is expected to report for Q4 2023 Charge Enterprises Inc. (CRGE) ...
Context Therapeutics Inc. (CNTX) is expected to report $-0.3 for Q3 2023
CTIM-76 exhibits dose-proportional tumor responses and safety in preclinical models Benchmarking studies comparing CTIM-76 with clinical-stage CLDN6 therapies support CTIM-76's differentiated product profile CTIM-76 IND filing on track for late Q1 2024 Data to be presented...
2023-10-05 12:59:42 ET More on Grupo Aeroportuario del Centro Norte, Grupo Aeroportuario del Pacifico, etc. For further details see: BTWN, OMAB and PAC among mid-day movers
2023-09-27 13:48:39 ET Gainers: ShiftPixy ( PIXY ) +92% . SciSparc Ltd ( SPRC ) +42% . MSP Recovery ( LIFW ) +41% . Biohaven ( BHVN ) +28% . MillerKnoll ( MLKN ) +28% . American Strategic Investment Co ( NYC ) +22% . ...
PHILADELPHIA, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a biopharmaceutical company advancing medicines for solid tumors, today announced a poster regarding the Company’s preclinical asset, CTIM-76,...
2023-08-10 14:26:07 ET Context Therapeutics press release ( NASDAQ: CNTX ): Q2 GAAP EPS of -$0.31. Cash and cash equivalents were $25.1 million at June 30, 2023, compared to $35.5 million at December 31, 2022. For further details see: Context Therapeutics GAAP EP...
--News Direct-- Context Therapeutics (NASDAQ:CNTX) CEO Marty Lehr takes Proactive's Stephen Gunnion through progress with the company's lead program, CTIM-76. Lehr explained that CTIM-76 is a T cell engaging bispecific antibody targeting Claudin 6 (CLDN6) on tumor cells and CD3 on...
News, Short Squeeze, Breakout and More Instantly...
Context Therapeutics Inc. Company Name:
CNTX Stock Symbol:
NASDAQ Market:
Context Therapeutics Inc. Website:
CT-95 is a potentially first-in-class mesothelin x CD3 bispecific antibody Acquisition expands Context pipeline with second clinical-stage T cell engager for solid tumors PHILADELPHIA, July 10, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the ...
Announced FDA clearance of IND application for a Phase 1 clinical trial of CTIM-76 Completed $100 million financing; expected to extend funding into 2028 PHILADELPHIA, May 08, 2024 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”...